The creative process of discovering novel pharmaceuticals based on the understanding of a biological target is known as Drug Design, sometimes known as rational drug design or simply rational design. A protein, for example, is a frequent example of a biomolecule whose activity is activated or inhibited by the medicine, which benefits the patient therapeutically. Drug design, in its most basic sense, is creating compounds that interact with and bind to biomolecular targets that are complementary to one another in shape and charge. Computer modelling methods are commonly but not always used in drug design. Computer-aided drug design is another name for this kind of modelling. The term "Structure-Based Drug Design" refers to drug development that is based on an understanding of the biomolecular target's three-dimensional structure. In addition to small molecules, Biopharmaceuticals, such as peptides and therapeutic antibodies, are a growingly significant class of medications. Computational techniques have also been developed to enhance the affinities, selectivities, and stabilities of these protein-based treatments.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia